Magnitude and management of HCV infection in France Christian TrépoFrançois Bailly OriginalPaper Pages: 22S - 26S
Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups Hans L. TillmannMichael P. Manns OriginalPaper Pages: 27S - 40S
Risk factors and prevention of hepatocellular carcinoma in HCV infection Luisa BenvegnùAlfredo Alberti OriginalPaper Pages: 49S - 55S
Modeling therapeutic benefit in the midst of uncertainty William G. BennettStephen G. PaukerJohn B. Wong OriginalPaper Pages: 56S - 62S
Nonhepatic manifestations and combined diseases in HCV infection Stephanos J. Hadziyannis OriginalPaper Pages: 63S - 74S
Health assessment for chronic HCV infection Robert L. Carithers Jr.David SuganoMartha Bayliss OriginalPaper Pages: 75S - 80S
High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C Wolfgang VogelIvo GraziadeiJosef Patsch OriginalPaper Pages: 81S - 85S
Duration of HCV infection as a predictor of nonresponse to interferon Antonio craxìVito Di MarcoSilvio Magrin OriginalPaper Pages: 86S - 92S
Two years versus six months of interferon therapy for chronic hepatitis C Geoffrey C. Farrell OriginalPaper Pages: 93S - 98S
Treatment of chronic hepatitis C by interferon for longer duration than six months Thierry PoynardVincent LeroyJean Pierre Zarski OriginalPaper Pages: 99S - 102S
Dose increase augments response rate to interferon-α in chronic hepatitis C Peter FerenciRudolf StauberAlfred Gangl OriginalPaper Pages: 103S - 108S
Short-term versus sustained response to interferon therapy Olle Reichard OriginalPaper Pages: 109S - 114S
Predictors of response to interferon therapy Giorgio SaraccoMario Rizzetto OriginalPaper Pages: 115S - 120S
Interferon-α therapy for chronic hepatitis C in special patient populations Patrick MarcellinNathalie BoyerSerge Erlinger OriginalPaper Pages: 126S - 130S
Interferon-ribavirin combination therapy for chronic hepatitis C Solko W. SchalmJ. T. BrouwerO. Weiland OriginalPaper Pages: 131S - 134S